The medical device industry as a whole experienced a handful of innovations in 2021, but Medical Tubing + Extrusion's reader took a special interest in two catheter-based innovations last year. Here are our most popular articles of 2021: Links to articles: Cook Medical wins FDA breakthrough device designation for next-gen … [Read more...] about The top stories from Medical Tubing + Extrusion in 2021
Abbott
Abbott sees the delivery system as a differentiator for its TAVR
A top Abbott executive explains how the company's FlexNav delivery system could make the Portico TAVR competitive. Abbott is aiming to claw away market share from transcatheter aortic valve replacement pioneers Edwards Lifesciences and Medtronic. The Abbott Park, Illinois–based medtech company in September announced FDA approval of its Portico … [Read more...] about Abbott sees the delivery system as a differentiator for its TAVR
FDA approves Abbott’s next-gen Epic Plus heart valves
Abbott (NYSE:ABT) announced today that it received FDA approval for its Epic Plus and Epic Plus Supra stented tissue valves. The approval offers improved therapy options for people with aortic or mitral valve disease through the next-generation devices that build off of Abbott’s Epic surgical valve platform, according to a news release. Get the … [Read more...] about FDA approves Abbott’s next-gen Epic Plus heart valves
Abbott acquires Walk Vascular and its system to remove peripheral blood clots
Abbott (NYSE:ABT) announced today that it acquired Walk Vascular and its minimally invasive mechanical aspiration thrombectomy system. Financial terms of the acquisition were not disclosed. Walk Vascular designed its JETi peripheral thrombectomy system and the next-generation JETi AIO (all-in-one) peripheral thrombectomy system to remove … [Read more...] about Abbott acquires Walk Vascular and its system to remove peripheral blood clots
FDA approves Abbott Amplatzer Amulet to treat AFib
Abbott this week announced that it has received FDA approval for its Amplatzer Amulet device to treat atrial fibrillation. The Amplatzer Amulet is a left atrial appendage occluder for treating atrial fibrillation (AFib) with a risk of ischemic stroke. The device is a small pouch connected to the upper left chamber of the heart. Get the full … [Read more...] about FDA approves Abbott Amplatzer Amulet to treat AFib
Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent
Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform. When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation. As a practicing interventional … [Read more...] about Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent
Abbott wins new FDA approvals for stent family including nod for next-gen Xience Skypoint
Abbott (NYSE:ABT) announced today that the Xience stent family received FDA approval for one-month dual antiplatelet therapy (DAPT) labeling. The FDA’s approval for one-month (as short as 28 days) DAPT labeling applies to high bleeding risk (HBR) patients in the U.S., according to a news release. The company also recently received CE mark … [Read more...] about Abbott wins new FDA approvals for stent family including nod for next-gen Xience Skypoint
How Abbott engineered a catheter-delivered device for premature babies
Abbott’s experience designing its Piccolo device provides essential lessons for medical device creators who want to spark a pediatric medical device renaissance. The Amplatzer Piccolo occluder from Abbott is one of the first medical devices that health providers can implant in premature babies weighing as little as 2 lb to treat patent ductus … [Read more...] about How Abbott engineered a catheter-delivered device for premature babies
4 catheter-based devices to watch for in 2021
Medical device companies are working to gain regulatory approvals and launch new catheter-based devices as the world slowly returns to normal after reeling from the COVID-19 pandemic. As of April 19, the FDA had approved 11 medical devices this year — two of them catheter-based. In comparison, the regulatory agency approved 19 devices by April … [Read more...] about 4 catheter-based devices to watch for in 2021
Abbott Xience stent gains expanded CE mark
Abbott (NYSE:ABT) announced today that its Xience stent received CE mark approval for a shorter duration of dual anti-platelet therapy (DAPT). The European approval for the stent allows for the DAPT to go as short as 28 days, the shortest indication available in the world for patients with high bleeding risk (HBR), according to a news … [Read more...] about Abbott Xience stent gains expanded CE mark
